Related Experiment Video
Updated: May 23, 2026

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
Published on: January 8, 2015
Molecular pathology, classification, and diagnosis of sporadic human prion disease variants
Piero Parchi1, Daniela Saverioni
1Department of Neurological Sciences, Universtity of Bologna, Via Foscolo 7, 40123, Bologna, Italy. piero.parchi@unibo.it
Abstract:
Human prion diseases are a unique group of transmissible neurodegenerative diseases that occur as sporadic, familial or acquired disorders and show a wide range of phenotypic variation. The latter has been attributed to the existence of distinct strains of the agent or prion, and the genetic background of the host, namely the primary sequence of the gene encoding the prion protein, which is the site of mutations and polymorphisms. The characterization of distinct isoforms of the abnormal prion protein in the brain of affected patients, which has been shown to correlate with the disease phenotype, has recently led to the concept of molecular strain typing, in which the different prion protein isoforms or "types", possibly enciphering the strain variability in their conformation, may serve as surrogate markers for individual prion strains. In sporadic Creutzfeldt-Jakob disease, the most common human prion disease, there are at least six distinct clinico-pathological disease phenotypes that largely correlate at a molecular level with two prion protein types with distinctive physicochemical properties and the genotype at the methionine/valine polymorphic codon 129 in the prion protein gene. Recent results of transmission studies indicate that five prion strains with distinctive biological properties can be isolated from these six disease variants. It has also been shown that about a third of sporadic cases show a mixed phenotype and the co-occurrence of prion protein types. The origin of prion strains and their co-occurrence as well as the mechanisms underlying the strain-specific neuronal targeting remain largely unexplained and their understanding constitute, together with the development of successful therapies and more sensitive and specific clinical biomarkers, the major challenges that this disease poses for the future.
Insights
Human prion diseases exhibit diverse phenotypes due to distinct prion strains and host genetics. Molecular strain typing, using prion protein isoforms, aids in classifying these neurodegenerative disorders.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Human prion diseases are transmissible neurodegenerative disorders with varied presentations.
- Phenotypic variation is linked to prion strains and host genetic factors, particularly the prion protein gene.
- Distinct abnormal prion protein isoforms correlate with disease phenotypes and are used for molecular strain typing.
Purpose of the Study:
- To explore the relationship between prion protein isoforms, host genetics, and disease phenotypes in human prion diseases.
- To understand the diversity and origins of prion strains and their mechanisms of neuronal targeting.
Main Methods:
- Characterization of distinct prion protein isoforms in affected patients' brains.
- Analysis of prion protein gene polymorphisms (e.g., codon 129).
- Transmission studies to isolate and characterize prion strains from disease variants.
Main Results:
- Six distinct clinico-pathological phenotypes in sporadic Creutzfeldt-Jakob disease correlate with two prion protein types and codon 129 genotype.
- Five distinct prion strains identified through transmission studies from these variants.
- Approximately one-third of sporadic cases show mixed phenotypes and co-occurring prion protein types.
Conclusions:
- Prion protein isoforms serve as surrogate markers for prion strains.
- The origin and co-occurrence of prion strains, along with mechanisms of neuronal targeting, require further investigation.
- Developing therapies and biomarkers are critical future challenges for human prion diseases.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Parkinson Disease ll: Pathophysiology
Subviral Agents
Fungal Phylum Microsporidia
Huntington Disease l: Introduction

